Search Results for :


Castle Biosciences’ DecisionDx-Melanoma Test Accurately Predicts Metastatic Risk in Patients with Head and Neck Melanoma

Friendswood, TX – May 1, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the prognostic accuracy of the DecisionDx®-Melanoma gene expression profile (GEP) test in a cohort of patients with head and neck melanoma. Results demonstrated that the DecisionDx-Melanoma test accurately … Read More


Blue Cross Blue Shield Association Evidence Street Issues Positive Assessment of Castle Biosciences’ Uveal Melanoma Gene Expression Test

Friendswood, TX – March 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Blue Cross Blue Shield Association Evidence Street™ has issued a positive assessment of DecisionDx®-UM, the Company’s gene expression profile (GEP) test to determine prognosis (metastatic potential) in patients diagnosed with uveal melanoma … Read More


Castle Biosciences’ DecisionDx-Melanoma Test Shown to be a Significant Predictor of Distant Metastasis in Elderly Patients with Melanoma

Friendswood, TX–March 20, 2017– Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that studies evaluating the prognostic performance and clinical impact of the DecisionDx®-Melanoma gene expression profile (GEP) test, including a cohort of elderly patients and four independent studies, were presented during the 70th Society of Surgical Oncology Annual Cancer … Read More


Study Demonstrates that DecisionDx-Melanoma Test Improves Identification of High Risk Skin Melanoma When Used with AJCC Outcome Prediction Tool

Friendswood, TX – January 23, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of results from a study comparing and combining risk prediction using DecisionDx®-Melanoma, the Company’s gene expression profile (GEP) test used to predict risk of metastasis in cutaneous melanoma (CM) patients, and … Read More


Castle Biosciences to Present at the Piper Jaffray 28th Annual Healthcare Conference

Friendswood, TX – November 22, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO, will be presenting at the Piper Jaffray 28th Annual Healthcare Conference on Tuesday, November 29th, 2016 at 4:50 p.m. EST in New York.
About Castle Biosciences
Castle … Read More


Castle Biosciences Announces Data Presentations at the Association for Molecular Pathology 2016 Annual Meeting with Gene Expression Profile Tests for Uveal and Cutaneous Melanoma

Friendswood, TX – November 14, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from studies evaluating clinical experience with gene expression profile (GEP) tests DecisionDx®-Melanoma and DecisionDx®-UM. In the studies, both GEP tests demonstrated a high technical success rate with robust, reproducible and reliable performance. … Read More


Castle Biosciences Announces Data Presentation at the Society for Melanoma Research 2016 Congress Demonstrating Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management

Friendswood, TX – November 10, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma on patient management decisions. The test uses tumor biology to provide an individual risk of recurrence in … Read More